

UC San Diego

UC San Diego Previously Published Works

Title

A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations

Permalink

<https://escholarship.org/uc/item/5kb1z6w4>

Journal

Scientific Reports, 10(1)

ISSN

2045-2322

Authors

Zhang, Zhiying
Hu, Kaiwen
Miyake, Kentaro
et al.

Publication Date

2020

DOI

10.1038/s41598-020-76708-9

Peer reviewed



OPEN

A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations

Zhiying Zhang^{1,2,3}, Kaiwen Hu³✉, Kentaro Miyake^{1,2}, Tasuku Kiyuna^{1,2}, Hiromichi Oshiro^{1,2}, Sintawat Wangsiricharoen¹, Kei Kawaguchi^{1,2}, Takashi Higuchi^{1,2}, Sahar Razmjooei¹, Masuyo Miyake^{1,2}, Sant P. Chawla⁴, Shree Ram Singh⁵✉ & Robert M. Hoffman^{1,2}✉

Liver metastasis is a recalcitrant disease that usually leads to death of the patient. The present study established a unique patient-derived orthotopic xenograft (PDOX) nude mouse model of a highly aggressive liver metastasis of colon cancer. The aim of the present study was to demonstrate proof-of-concept that candidate drug combinations could significantly inhibit growth and re-metastasis of this recalcitrant tumor. The patient's liver metastasis was initially established subcutaneously in nude mice and the subcutaneous tumor tissue was then orthotopically implanted in the liver of nude mice to establish a PDOX model. Two studies were performed to test different drugs or drug combination, indicating that 5-fluorouracil (5-FU) + irinotecan (IRI) + bevacizumab (BEV) and regorafenib (REG) + selumetinib (SEL) had significantly inhibited liver metastasis growth ($p = 0.013$ and $p = 0.035$, respectively), and prevented liver satellite metastasis. This study is proof of concept that a PDOX model of highly aggressive colon-cancer metastasis can identify effective drug combinations and that the model has future clinical potential.

Liver metastasis is a major cause of death for common cancers and is very frequent in colon cancer¹. Surgery for liver metastasis does not usually lead to cures¹. For colon cancer, chemotherapy including FOLFIRI, the combination of folinic acid (FOL), fluorouracil (5-FU) and irinotecan (IRI); FOLFOX, the combination of FOL, 5-FU and oxaliplatin (OXA); CAPEOX, the combination of capecitabine (CAPE) and OXA; or FOLFOXIRI, the combination of FOL, 5-FU, OXA and IRI plus targeted therapy such as bevacizumab (BEV), regorafenib (REG), panitumumab (PAN) or cetuximab (CET) are used to treat liver metastasis¹⁻³. The outcome of such chemotherapy is variable and appears to be patient specific³⁻⁶. Yondelis (trabectedin, YON) is an alkylating drug for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen⁷. Selumetinib (SEL) is a non-ATP-competitive mitogen-activated protein kinase 1 and 2 (MEK1 and MEK2) inhibitor⁸. YON and SEL have not yet been used for metastatic colon cancer in the clinic.

In order to develop individualized precision treatment for cancer, we have developed the patient-derived orthotopic xenograft (PDOX) mouse model. Tumor fragments from the patient are implanted into the corresponding anatomic location (orthotopic) in the nude mouse via surgical orthotopic implantation (SOI). We have successfully established PDOX models of all major cancer types⁹⁻²². We demonstrated that the PDOX model is superior to the subcutaneous patient-derived xenograft (PDX) model due to the proper tumor microenvironment which enables tumor invasion and metastasis^{23,24}, matching the patient metastatic pattern^{14,25}.

¹AntiCancer, Inc., San Diego, CA, USA. ²Department of Surgery, University of California, San Diego, CA, USA. ³Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China. ⁴Sarcoma Oncology Center, Santa Monica, CA, USA. ⁵Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. ✉email: kaiwenh@163.com; singhshr@mail.nih.gov; all@anticancer.com




Figure 1. Schematic diagram of surgical orthotopic implantation (SOI) for the colon cancer liver-metastasis model. After the patient's liver-metastasis surgery, intact liver metastasis tumor tissue from the patient was initially implanted subcutaneously into nude mice to establish a stable patient-derived xenograft (PDX) model, defined as P0. After the P0 tumor grew to approximately 1 cm in diameter, the mice were sacrificed and the subcutaneous tumors were harvested, viable tumor tissue was minced into 2 mm³ fragments for orthotopic transplantation into the liver of the nude mice to establish a patient-derived orthotopic xenograft (PDOX) model. Please see materials and methods for details.

In the present study, we established a PDOX model of a highly-aggressive colon cancer liver metastasis by implanting a fragment of a highly metastatic colon cancer directly into the liver in the nude mouse. The PDOX model enabled the identification of two candidate effective combination regimens that arrested liver metastasis growth and prevented satellite-metastasis formation, and demonstrated proof-of-concept that such combinations could be identified with this unique PDOX model of highly-metastatic patient colon cancer.

Materials and methods

Mice. Athymic nude mice (AntiCancer, Inc., San Diego, CA), 4–6 weeks old, were used^{17–23}. Procedures for mouse housing, handling, anesthesia, feeding, and humane endpoint criteria have been previously described^{17–23}. In order to minimize any suffering of the animals, anesthesia and analgesics were used for all surgical experiments as previously described^{17–23}. The animal studies were conducted in compliance with an AntiCancer, Inc. Institutional Animal Care and Use Committee (IACUC) protocol exclusively approved for this study and in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1²¹.

Patient-derived tumor. A patient diagnosed with colon cancer liver metastasis had the metastatic tumor resected in Scripps Clinic, San Diego. Written informed consent was provided by the patient, and the Institutional Review Board (IRB) of Scripps Clinic approved this experiment. Experiments in the present study were performed per the Declaration of Helsinki guidelines and in agreement with national regulations for the experimental use of human material.

Establishment of PDOX models of colon cancer liver metastasis. After surgical resection of the patient, a fresh tumor sample was transferred immediately to the laboratory in AntiCancer, Inc. in a sterile tube with RPMI-1640 medium. The tube was put in ice to maintain the temperature at 4 °C²². The sample was divided into small fragments and implanted subcutaneously into both flanks of nude mice to establish a patient-derived xenograft (PDX) model. When the subcutaneous tumors grew over 10 mm in diameter, the tumors were harvested and inspected, and any suspected or grossly necrotic tissue was removed. Healthy tumor tissues were subsequently cut into small fragments of approximately 2 mm³. After anesthesia, a 1 cm skin incision was made along with the anterior abdominal midline of the nude mouse using surgical scissors. The liver lobe was exposed, the capsule at the transplantation site was stripped, and one tumor fragment was implanted and fixed with 8–10 surgical sutures (nylon). The liver was replaced into the abdomen and the abdomen was closed with 6–10 surgical sutures (Ethilon, Ethicon, Inc., NJ) (Fig. 1)²².

Treatment study design in the colon-cancer liver-metastasis PDOX model. The tumor volume and body weight were measured every 2 weeks after laparotomy using electronic calipers and an electronic scale, respectively. Calipers could be used since the tumor was growing mostly on the surface of the liver. The tumor volume was estimated by measuring the perpendicular minor dimension (W) and major dimension (L). Approximate tumor volume was calculated by the formula $(W^2 \times L)/2$. When the volume of tumors reached approximately 60 mm³, the mice were randomized into 4 groups. For the first study, the mice with liver-implanted tumors were divided as follows: Group 1, untreated control (n = 5); Group 2, 5-FU + IRI + BEV (n = 6); Group 3, 5-FU + OXA + BEV (n = 6); and Group 4, 5-FU + BEV (n = 5). The treatment period was 4 weeks. For the second study, when the volume of tumors reached approximately 60 mm³, the mice with liver-implanted tumors were also randomized into 4 groups: Group 1, untreated control (n = 6); Group 2, YON + OXA (n = 4); Group 3, REG alone (n = 7); and Group 4, SEL + REG (n = 5). There were 6 mice in each group. The treatment period was 2 weeks. The treatment protocol is shown in Table 1. The drug doses were determined by published

Group	Treatment	Route	Dose	Frequency
Study 1				
1	Control	ip	200 μ L (PBS)	Once a week
2	5-Fluorouracil	ip	50 mg/kg	Once a week
	Irinotecan	ip	40 mg/kg	Twice a week
	Bevacizumab	ip	5 mg/kg	Twice a week
3	5-Fluorouracil	ip	50 mg/kg	Once a week
	Oxaliplatum	ip	6 mg/kg	Once a week
	Bevacizumab	ip	5 mg/kg	Twice a week
4	Fluorouracil	ip	50 mg/kg	once a week
	Bevacizumab	ip	5 mg/kg	Twice a week
Study 2				
1	Control	ip	200 μ L (PBS)	Once a week
2	Yondelis	iv	0.15 mg/kg	Once a week
	Oxaliplatum	ip	6 mg/kg	Twice a week
3	Regorafenib	po	30 mg/kg	Once a day
4	Selumetinib	po	20 mg/kg	Once a day
	Regorafenib	po	30 mg/kg	Once a day

Table 1. Treatment protocol for the colon-cancer liver-metastasis PDOX model. The mice were randomized into 4 different groups. For study one, the treatment period was 4 weeks. For study two, the treatment period was 2 weeks.

literature^{26–38}. At the end of the study, the mice were euthanized by CO₂ inhalation, the tumors were harvested, and directly measured. The images of the mice and the tumors were obtained with the OV100 Small Animal Imaging System (Olympus Corporation, Tokyo, Japan)²².

Histological examination. Freshly-harvested tumors and liver tissue were fixed in 10% formalin and embedded in paraffin for further histology analysis. Tissue sections (5 mm) were deparaffinized in ClearRite and rehydrated in an ethanol series. Hematoxylin and eosin (H and E) staining was performed according to standard protocols²². Histological examination was performed with a BHS System Microscope (Olympus Corporation)²². Histological images were obtained with INFINITY ANALYZE 7 software (Lumenera Corporation, Ottawa, Canada)²², no software license is needed.

Statistical analysis. IBM SPSS Statistics Version 24.0 (IBM, New York City, NY) was used for statistical analyses in this study. The Shapiro–Wilk test was used to assess the normal distribution. Bartlett’s test was used to verify the homogeneity of variances among groups. One-way ANOVA with Tukey HSD for post hoc analysis was used for the parametric test, and the Kruskal–Wallis one-way ANOVA with Steel–Dwass for post hoc analysis was used for the non-parametric comparison. Data are shown as mean \pm standard deviation (SD). A *p* value of 0.05 or less indicates statistical significance.

Results

Orthotopic tumor growth in the liver. The untreated PDOX tumor grew extremely aggressively in the control-group mice, mimicking the liver metastasis in the patient (Fig. 2G,H).

Drug efficacy in the colon-cancer liver-metastasis PDOX model. In the first study, the two-week measurement made in situ with calipers is consistent with the endpoint measurement of the harvested tumor at 4 weeks. The relative tumor volume in the various groups, which is the ratio of the post-treatment tumor volume to pre-treatment tumor volume, was as follows after the 4-week treatment period: Group 1, control: 5.24 ± 2.97 ; Group 2, 5-FU + BEV: 2.03 ± 0.88 ; Group 3, 5-FU + OXA + BEV: 3.07 ± 1.19 ; Group 4, 5-FU + IRI + BEV: 1.13 ± 0.80 . Only Group 4, 5-FU + IRI + BEV significantly inhibited the growth of the colon cancer liver metastasis in the PDOX model compared with the untreated control (*p* = 0.013). The growth of the liver metastasis was arrested by the combination of 5-FU + IRI + BEV (Fig. 2A,B).

In the second study, the relative tumor volume was as follows after the 2-week treatment period: Group 1, control: 5.53 ± 2.52 ; Group 2, YON + OXA: 3.46 ± 3.09 ; Group 3, REG: 2.38 ± 1.01 ; Group 4, SEL + REG: 1.7 ± 0.19 . Only Group 4, SEL + REG significantly inhibited the growth of the colon cancer liver metastasis in the PDOX model compared with the untreated control (*p* = 0.035). The growth of the liver metastasis was almost arrested by the combination of SEL + REG (Fig. 2C,D).

Drug efficacy on satellite metastasis. In the first study, intrahepatic metastases were observed in Group 1, control (3 mice, 10 metastases); Group 2, 5-FU + BEV (1 mouse, 1 metastasis) and Group 3, 5-FU + OXA + BEV




Figure 2. Drug efficacy testing. For the first study, untreated control (n = 5); 5-FU + BEV (n = 6), 5-FU + OXA + BEV (n = 6); 5-FU + IRI + BEV (n = 5). For the second study, untreated control (n = 6); YON + OXA (n = 4), REG (n = 7); SEL + REG (n = 5). **(A)** Study 1, comparison of tumor volume before treatment; at 2 weeks; and after treatment. **(B)** Study 1, comparison of relative tumor volume before treatment; at 2 weeks; and after 4 weeks. **(C)** Study 2, comparison of tumor volume before treatment and after treatment. **(D)** Study 2, comparison of relative tumor volume before treatment and after treatment. The data are shown as mean + standard deviation (SD). **(E)** Study 1, representative images of a harvested tumor in each group. The white arrow shows the intrahepatic metastasis along with the primary implanted tumor. Scale bar: 10 mm. **(F)** Study 2, representative images of harvested tumor in each group. **(G):** Study 1, representative images of the control and treated tumors. **(H)** Study 2, representative images of the control and treated tumors.

Group	Mouse number with metastasis	Total number of satellite metastasis in the group
Study 1		
Control	3	10
5-FU + BEV	1	1
5-FU + OXA + BEV	2	2
5-FU + IRI + BEV	0	0
Study 2		
Control	1	6
YON + OXA	1	2
REG	2	3
SEL + REG	0	0

Table 2. Intra-hepatic satellite metastases. Total satellite metastases were identified at necropsy.

(2 mice, 2 metastases). Group 4, 5-FU + IRI + BEV prevented intra-hepatic metastases, as well as arrested tumor growth. (Table 2, Fig. 2E,G).

In the second study, intrahepatic metastases were observed in Group 1, control (1 mouse, 6 metastases); Group 2, YON + OXA (1 mouse, 2 metastases) and Group 3, REG (2 mice, 3 metastases) (Table 2). Group 4, SEL + REG prevented intra-hepatic metastases, as well as almost arresting tumor growth. (Table 2, Fig. 2F,H).

Effect of drugs on mouse body weight. We measured the mouse body weight every two weeks to monitor the overt toxicity of the drugs. There was no significant body-weight loss in any group at the end of this study. (Fig. 3A,B).

Effect of drugs on tumor histology. We analyzed the tumor histology in each group to examine whether the drug combinations could induce necrosis (Fig. 4). In the first study, Group 1, control, showed a classic morphology for colon adenocarcinoma with pleomorphism and a small extent of necrosis. Group 2, 5-FU + BEV, showed a moderate extent of treatment-related tumor necrosis. There was a similar degree of treatment-related tumor necrosis in Group 3, 5-FU + OXA + BEV. In contrast, in Group 4, 5-FU + IRI + BEV, the tumor had extensive treatment-related necrosis. In the first study, treatment efficacy, measured by tumor necrosis, was significantly higher in the 5-FU + IRI + BEV group than the 5-FU + OXA + BEV; 5-FU + BEV; and control groups ($p < 0.05$) (Fig. 4E). In the second study, Group 1, control, also showed a classic morphology for colon




Figure 3. Effect of drugs on body weight. The Kruskal–Wallis one-way ANOVA test was used to analyze the differences between each group. The data are shown as mean + SD.




Figure 4. Effect of drugs on tumor histology. (A) Control group. (B) 5-FU + BEV group. (C): 5-FU + OXA + BEV group. (D): 5-FU + IRI + BEV group. (E) Extent of tumor necrosis. (F) Control group. (G) YON + OXA group. (H): REG group. (I) SEL + REG group. (J) Extent of tumor necrosis. *Mean $p < 0.05$. Scale bar: 200 μm . Images were obtained with INFINITY ANALYZE 7 software, <https://www.lumenera.com/products/microscopy/infinity-analyze.html>.

adenocarcinoma with pleomorphism and a small extent of necrosis. Group 2, YON + OXA, showed a moderate extent of treatment-related tumor necrosis. In Group 3, REG and Group 4, SEL + REG, the tumor had extensive treatment-related necrosis. Treatment efficacy measured by tumor necrosis was significantly higher in the REG alone group and SEL + REG group than the YON + OXA and control groups ($p < 0.05$). (Fig. 4J).

Discussion

In the present report, we found that the combination of 5-FU, IRI and BEV as well as the combination of SEL and REG showed the best efficacy on the liver-metastasis PDOX, arresting or almost arresting liver-metastasis growth and preventing satellite metastases within the liver. The combination of 5-FU, OXA and BEV, the combination of 5-FU and BEV, the combination of YON and OXA as well as REG alone did not show significant anti-tumor efficacy. The combination of 5-FU, IRI and BEV, and the combination of SEL and REG and REG alone demonstrated a high level of tumor necrosis ($p < 0.05$), indicating a high level of cancer-cell killing. This PDOX model

for this liver-metastatic colon cancer thus clearly distinguished two candidate effective combinations for this highly-aggressive liver-metastasis PDOX.

Intrahepatic satellite metastases occurred in this study, which also demonstrated the power of the PDOX model, in this case to identify the extreme malignancy of the original tumor (Fig. 2G,H), and then target it with appropriate therapy. Subcutaneous PDX models very rarely develop metastasis^{24,25}. Since this is a liver metastasis of colon cancer, the microenvironment in the liver enabled the aggressiveness of the tumor to be expressed^{39,40}.

The effective drug combinations were identified 7 months and 12 months after the surgery, in study 1 and 2 respectively, demonstrating the potential of PDOX model for the clinician to decide optimal second-line therapy, which is often needed as first-line therapy for colon-cancer metastasis often fails. Future studies will correlate drug response in the PDOX model and the patient.

Conclusion

The present report was on a PDOX model of an extremely aggressive liver-metastasis model, that could grow extensively in the liver to form a large tumor as well as form satellite re-metastasis in the liver. The present study showed it was possible to inhibit this aggressive metastasis tumor with combination chemotherapy, which was proof-of-concept that this model could be used to identify new combination therapy for liver metastasis as well as for 2nd-line or later therapy for patients in the future.

Received: 27 February 2020; Accepted: 29 October 2020

Published online: 18 November 2020

References

1. Cameron, J. L. & Cameron, A. M. *Current Surgical Therapy* (Elsevier, Amsterdam, 2013).
2. National Comprehensive Cancer Network. Colon Cancer (Version 4.2020). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (2020).
3. Alberts, S. R. & Wagman, L. D. Chemotherapy for colorectal cancer liver metastases. *Oncologist* **13**, 1063–1073 (2008).
4. André, T. *et al.* Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N. Engl. J. Med.* **350**, 2343–2351 (2004).
5. Pfeiffer, P., Gruenberger, T. & Glynne-Jones, R. Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?. *Ther. Adv. Med. Oncol.* **10**, 1758835918787993 (2018).
6. Sanoff, H. K. *et al.* Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. *JCO* **30**, 2624–2634 (2012).
7. Barone, A. *et al.* FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen. *Clin. Cancer Res.* **23**, 7448–7453 (2017).
8. Seto, T. *et al.* Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. *Jpn. J. Clin. Oncol.* **48**, 31–42 (2018).
9. Hiroshima, Y. *et al.* Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. *J. Laparoendosc. Adv. Surg. Tech. A* **24**, 241–247 (2014).
10. Fu, X. Y., Besterman, J. M., Monosov, A. & Hoffman, R. M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. *PNAS* **88**, 9345–9349 (1991).
11. Wang, X., Fu, X. & Hoffman, R. M. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. *Int. J. Cancer* **51**, 992–995 (1992).
12. Fu, X., Guadagni, F. & Hoffman, R. M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. *Proc. Natl. Acad. Sci.* **89**, 5645–5649 (1992).
13. Kawaguchi, K. *et al.* Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. *Cancer Lett.* **432**, 251–259 (2018).
14. Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M. & Hoffman, R. M. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. *Int. J. Cancer* **53**, 608–612 (1993).
15. Fu, X., Le, P. & Hoffman, R. M. A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. *Anticancer Res.* **13**, 901–904 (1993).
16. Fu, X. & Hoffman, R. M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. *Anticancer Res.* **13**, 283–286 (1993).
17. Hiroshima, Y. *et al.* Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. *PLoS ONE* **10**, e0117417 (2015).
18. Astoul, P., Colt, H. G., Wang, X., Boutain, C. & Hoffman, R. M. “Patient-Like” nude mouse metastatic model of advanced human pleural cancer. *J. Cell. Biochem.* **56**, 9–15 (1994).
19. Yamamoto, M. *et al.* Efficacy of tumor-targeting salmonella A1-R on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *PLoS ONE* **11**, e0160882 (2016).
20. Kiyuna, T. *et al.* High efficacy of tumor-targeting *Salmonella typhimurium* A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. *Oncotarget* **7**, 33046–33054 (2016).
21. Igarashi, K. *et al.* Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy. *J. Cell. Biochem.* **119**, 6598–6603 (2018).
22. Zhang, Z. *et al.* A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. *Pharmacol. Res.* **142**, 169–175 (2019).
23. Igarashi, K. *et al.* Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. *Cell Cycle* **16**, 91–94 (2017).
24. Hiroshima, Y. *et al.* Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. *Oncotarget* **7**, 71696–71702 (2016).
25. Hoffman, R. M. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. *Nat. Rev. Cancer* **15**, 451–452 (2015).
26. Damiano, V. *et al.* TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. *Proc. Natl. Acad. Sci. USA* **104**, 12468–12473 (2007).

27. Gardner, E. R. *et al.* Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. *Invest New Drugs* **30**, 90–97 (2012).
28. Hiroshima, Y. *et al.* Efficacy of tumor-targeting *Salmonella typhimurium* A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. *Oncotarget* **5**, 12346–12357 (2014).
29. Robinson, S. M. *et al.* Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. *J. Hepatol.* **59**, 318–326 (2013).
30. Limani, P. *et al.* Antihypoxic potentiation of standard therapy for experimental colorectal liver metastasis through Myo-Inositol trispyrophosphate. *Clin. Cancer Res.* **22**, 5887–5897 (2016).
31. Ikemura, M. & Hashida, T. Effect of hyperglycemia on antitumor activity and survival in tumor-bearing mice receiving oxaliplatin and fluorouracil. *Anticancer Res.* **37**, 5463–5468 (2017).
32. Ohwada, S. *et al.* Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. *Cancer Lett.* **110**, 149–154 (1996).
33. Motwani, M., Sirotnak, F. M., She, Y., Commes, T. & Schwartz, G. K. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. *Cancer Res.* **62**, 3950–3955 (2002).
34. Ji, Y. *et al.* The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. *Anticancer Res.* **27**, 713–718 (2007).
35. Kiyuna, T. *et al.* Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. *BMC Cancer* **18**, 840 (2018).
36. Daudigeos-Dubus, E. *et al.* Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models. *PLoS ONE* **10**, e0142612 (2015).
37. Dombi, E. *et al.* Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. *N. Engl. J. Med.* **375**, 2550–2560 (2016).
38. Weisberg, E. *et al.* Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. *Clin. Cancer Res.* **20**, 5483–5495 (2014).
39. Kuo, T. H. *et al.* Liver colonization competence governs colon cancer metastasis. *Proc. Natl. Acad. Sci. USA* **92**, 12085–12089 (1995).
40. Chishima, T. *et al.* Governing step of metastasis visualized in vitro. *PNAS USA* **94**(21), 11573–11576 (1997).

Acknowledgements

This paper is dedicated to the memory of A. R. Mossa, MD; Sun Lee, MD; Prof. Li Jiaxi and Masaki Kitajima, MD.

Author contributions

Z.Z., K.H. and R.M.H. were involved in study conception and design. Z.Z., K.H., K.M., T.K. H.O., S.W. K.K. T.H., S.R., and M.M. were involved in acquisition of data. Z.Z., K.H., K.M., T.K. H.O., S.W. K.K. T.H., S.R., and M.M., S.P.C., S.R.S., and R.M.H. analyzed and interpreted the data. Z.Z. and R.M.H. prepared the manuscript. S.R.S. was involved in critical revision of the manuscript. All authors reviewed the manuscript.

Competing interests

AntiCancer Inc. uses PDOX models for contract research. Z.Z., K.M., T.K. H.O., S.W. K.K. T.H., S.R., M.M., and R.M.H. are or were unsalaried associates of AntiCancer Inc. There are no other competing financial interests.

Additional information

Correspondence and requests for materials should be addressed to K.H., S.R.S. or R.M.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020